1	Risk of Second Primary Cancers After a Diagnosis of First Primary Cancer: A
2	Pan-Cancer Analysis and Mendelian Randomization Study
3	
4	Xiaohao Ruan ^{1†} , Da Huang ^{1†} , Yongle Zhan ² , Jingyi Huang ¹ , Jinlun Huang ¹ , Ada
5	Tsui-Lin NG ² , James Hok-Leung TSU ² , Rong Na ^{2*} .
6	
7	1. Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of
8	Medicine, Shanghai 200025, China.
9	2. Division of Urology, Department of Surgery, Queen Mary Hospital, The University
10	of Hong Kong, Hong Kong, China.
11	[†] Xiaohao Ruan and Da Huang contributed equally to this work.
12	*Corresponding Author.
13	Rong Na,
14	Division of Urology, Department of Surgery, Queen Mary Hospital, The University of
15	Hong Kong, Hong Kong, China
16	Tel: +852-22554310; Email address: <u>narong.hs@gmail.com</u> .
17	No. of Words:
18	Abstract: 238 words
19	Text: 2956 words
20	
21	

22 Abstract

23	Background: The risk of second primary cancers (SPC) is increasing after the first
24	primary cancers (FPC) are diagnosed and treated. The underlying causal relationship
25	remains unclear.
26	Methods: We conducted a pan-cancer association (26 cancers) study in the
27	Surveillance, Epidemiology, and End Results (SEER) database. The standardized
28	incidence ratio (SIR) was estimated as the risk of SPCs in cancer survivors based on the
29	incidence in the general population. Furthermore, the causal effect was evaluated by
30	two-sample Mendelian Randomization (MR, 13 FPCs) in the UK Biobank (UKB,
31	n=459,136) and robust analysis (radial MR and Causal Analysis Using Summary Effect
32	estimates, CAUSE).
33	Results: We found 11 significant cross-correlations among different cancers after
34	harmonizing SIR and MR results. Whereas only 4 of them were confirmed by MR to
35	have a robust causal relationship. In particular, patients initially diagnosed with oral
36	pharyngeal cancer would have an increased risk of non-Hodgkin lymphoma
37	pharyngeur euneer would nuve un mereused fisk of non frougkin fympholia
01	(SIR _{SEER} =1.18, 95%Confidence Interval [CI]:1.05-1.31, OR _{radial-MR} =1.21,
38	$(SIR_{SEER}=1.18, 95\%Confidence Interval [CI]:1.05-1.31, OR_{radial-MR}=1.21, 95\%CI:1.13-1.30, P=6.00\times10^{-3}; OR_{cause}=1.17, 95\%CI:1.05-1.31, P=8.90\times10^{-3}).$
38 39	$(SIR_{SEER}=1.18, 95\%Confidence Interval [CI]:1.05-1.31, OR_{radial-MR}=1.21, 95\%CI:1.13-1.30, P=6.00\times10^{-3}; OR_{cause}=1.17, 95\%CI:1.05-1.31, P=8.90\times10^{-3}).$ Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer
38 39 40	$(SIR_{SEER}=1.18, 95\%Confidence Interval [CI]:1.05-1.31, OR_{radial-MR}=1.21, 95\%CI:1.13-1.30, P=6.00\times10^{-3}; OR_{cause}=1.17, 95\%CI:1.05-1.31, P=8.90\times10^{-3}).$ Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer $(SIR_{SEER}=1.72, 95\%Confidence Interval [CI]:1.08-2.60, OR_{radial-MR}=1.39,$
 38 39 40 41 	$(SIR_{SEER}=1.18, 95\%Confidence Interval [CI]:1.05-1.31, OR_{radial-MR}=1.21, 95\%CI:1.13-1.30, P=6.00\times10^{-3}; OR_{cause}=1.17, 95\%CI:1.05-1.31, P=8.90\times10^{-3}).$ Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer (SIR_{SEER}=1.72, 95%Confidence Interval [CI]:1.08-2.60, OR_{radial-MR}=1.39, 95%CI:1.22-1.58, P=1.07\times10^{-3}; OR_{cause}=1.36, 95\%CI:1.16-1.58, P=0.01). And kidney

43	95%Confidence Interval	[CI	:1.22-1.35, OR _{radial-MR} =	1.17	,95%CI:1.08-1.27
----	------------------------	-----	---------------------------------------	------	------------------

- 44 $P=6.60\times10^{-3}$; OR_{cause}=1.16, 95%CI:1.02-1.31, P=0.05) and myeloma (SIR_{SEER}=1.54,
- 45 95%Confidence Interval [CI]:1.33-1.78, OR_{radial-MR}=1.24, 95%CI:1.21-2.45, *P*=0.02;
- 46 OR_{cause}=1.49, 95%CI:1.04-2.34, *P*=0.02).
- 47 **Conclusions**: A certain type of primary cancer may cause another second primary
- 48 cancer, and the profound mechanisms need to be studied in the future.
- 49 Funding: This work was in supported by grants from National Natural Science
- 50 Foundation of China (Grant No. 81972645), Innovative research team of high-level
- 51 local universities in Shanghai, Shanghai Youth Talent Support Program, intramural
- 52 grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program
- 53 (22YF1440500) to Dr. Da Huang.
- 54 **Keywords**: First primary cancer; Mendelian Randomization study; Pan-cancer
- 55 analysis; Second primary cancer.

56

57 Introduction

58	Cancer incidence is rapidly growing worldwide in the past decades. The reasons
59	are complex including the aging of the population, the application of screening,
60	environmental risk factors and genetic risk factors(Sung et al., 2021). In 2020, there
61	were an estimated 19.3 million new cases and 10.0 million deaths of different types of
62	cancers globally(Sung et al., 2021). In the US, there would be about 1.9 million new
63	cases of cancers in 2022, and the most common type of cancers in the male and the
64	female were prostate cancer (27%) and breast cancer (31%), respectively(Siegel et al.,
65	2022). Despite the rapidly increased incidence of cancers, the survival of (most types of)
66	cancers in the US has vastly improved since the mid-1970s with medical advances and
67	technical developments(Siegel et al., 2022). For example, the 5-year relative survival
68	rates of prostate cancer, melanoma, and female breast cancer, during 2011-2017 in the
69	US were 98%, 93%, and 90%, respectively(Siegel et al., 2022). Such disparity may lead
70	to an increase in the prevalence and the tumor burden in US society. More importantly,
71	prolonged survival makes it possible for individuals to be diagnosed with a second
72	primary cancer (SPC) after the first primary cancer (FPC) during the follow-up.
73	According to the Italian (1976-2010)("Italian cancer figures, report 2013:
74	Multiple tumours," 2013), the Swiss (1981-2009)(Feller et al., 2020), and the Swedish
75	(1990-2015)(Zheng et al., 2020) cancer registration data, increased risks of SPCs were
76	observed in many types of cancer as the FPCs. Patients with oral cavity & pharynx,
77	larynx, and esophagus as FPC were found to have a significantly elevated risk of any

78	SPCs in both Italy and Switzerland(Feller et al., 2020; "Italian cancer figures, report
79	2013: Multiple tumours," 2013). In Sweden, liver cancers, as well as nasal and oral
80	cancers, were found to be associated with SPCs(Zheng et al., 2020). In addition, several
81	studies focused on certain cancer also suggested a potential relationship between FPC
82	and SPC(Chattopadhyay et al., 2018). For example, increased FPC risk of colorectal
83	cancer, kidney cancer, and melanoma were observed following the diagnosis of
84	non-Hodgkin lymphoma. Despite the strong association observed in these studies,
85	whether there is any underlying causal relationship is unknown, or the association
86	observed is due to the potential confounders such as aging.
87	In the present study, our objectives are to perform a pan-cancer association
88	study in the Surveillance, Epidemiology, and End Results (SEER) and to interpret the
89	underlying causal relationship via Mendelian Randomization approaches using genetic
90	variants in a large population cohort (UK Biobank, UKB). In addition, the study may
91	also help us understand critical questions in clinical practice about who should be more
92	careful of the second primaries, and who should take precision screenings against
93	certain cancers in addition to the regular follow-up evaluations.
94	

95 **Results**

We set out to identify the observational association between FPCs and SPCs among 22 solid tumors and 4 hematological malignancies based on the SEER database (**Figure 1**). A total of 264 significant standardized incidence ratio (SIR)

5

99 existed among them when compared to a standard population (Table S1-17). 100 Hierarchical clustering analysis (heatmap) is shown in **Figure 2** which illustrates the 101 comparison between the cancer incidence in patients with a certain type of FPC and the 102 incidence in the population average level in the SEER dataset. Second primary thyroid 103 cancer, small bowel cancer, or cancers of endocrine system were strongly and 104 significantly associated with most of the FPCs. Cancers of the digestive system, 105 cervix uteri, as well as lung cancer were clustered together. They are closely 106 correlated with an increased risk of several types of cancers such as bladder cancer, 107 kidney cancer, etc. Our subgroup analysis suggested that patients with prostate cancer 108 who received radiation therapy were at an increased risk of being diagnosed with 109 another type of primary cancer during the follow-up including small intestine, soft 110 tissue, and leukemia, compared with those without such therapy (Table S13). And 111 SPC risk after breast cancer was inconsistent among males and females. Men with 112 breast cancer had a higher risk for thyroid cancer and prostate cancer (SIR_{SEER}=1.30; 113 95% CI, 1.13-1.49; SIR_{SEER}=2.33, 1.12-4.29; **Table S10**), but with no significant risk 114 change for other cancers.

Details of the included exposure-associated SNPs in European ancestry were shown in **Table 1** and **Table S18**. The number of SNPs ranged from 5 (esophagus) to 104 (female breast), and the proportion of variance explained by SNPs (R²) ranged from 0.10% (thyroid) to 8.46% (bladder). F-statistics for all 13 cancers exceeded 10, suggesting no weak instrument bias here. However, some problems, including too few

120	SNPs, no related GWAS and disease heterogeneity, affected the comprehensive MR
121	analysis (Table 1). Due to the low incidence of cancers in UKB, the power to detect a
122	significant effective size $(0.8/1.2)$ was relatively low, except for colorectal cancer, lung
123	cancer, female breast cancer and prostate cancer (Table S19).
124	Results from MR analyses are presented in Table S20-33. A total of 23 significant
125	association was detected (16 positive causality and 7 negative causality). Concordant
126	significant results and unconcordant results between MR and the SEER SIR analyses
127	are shown in Table 2 and Table S20, respectively. The concordant results suggested
128	that patients diagnosed with primary oral and pharynx cancer would cause a
129	significantly increased risk of second primary non-Hodgkin lymphoma (SIR _{SEER} = 1.18 ,
130	95% CI: 1.05-1.31; IVW-MR $P=8.96\times10^{-4}$). After a primary diagnosis of pancreatic
131	cancer, SPC risks were increased for small intestine (SIR _{SEER} =4.37, 95% CI: 2.85-6.40;
132	MR-Egger $P=0.04$). It also indicated that female patients initially diagnosed with
133	melanoma would cause a mild but significantly increased risk of cancers in the breast
134	(SIR _{SEER} =1.17, 95% CI: 1.12-1.23; IVW-MR <i>P</i> =0.04), as well as ovary cancer on soft
135	tissue related cancer (SIR _{SEER} =1.72, 95% CI: 1.08-2.60; IVW-MR P =8.39×10 ⁻⁵). The
136	greatest number of casual relationships were observed in kidney cancer as FPC. A
137	primary kidney cancer might cause an elevated risk of cancers of lung and bronchus
138	(SIR _{SEER} =1.28, 95% CI: 1.23-1.45; IVW-MR P=0.01), non-Hodgkin lymphoma
139	$(SIR_{SEER}=1.19, 95\% \text{ CI: } 1.08-1.31; \text{ IVW-MR } P=3.64\times10^{-3}), \text{ myeloma } (SIR_{SEER}=1.54, \text{ myeloma } 1.54\%)$
140	95% CI: 1.33-1.78; IVW-MR $P=3.94\times10^{-3}$). Meanwhile, some primary cancer site

141 might give protective effect against another cancer (for instance, lung cancer vs.

female breast cancer, Table 2). Scatter plot, Funnel plot, forest plot and leave-one-out
analysis showed single SNP effective size in Figure S1-4, respectively.

144 More conservative analyses were performed to further confirm these causal 145 relationships. We applied 2 outlier-detected methods with modified second order 146 weights (radial IVW and radial MR-Egger) and CAUSE (Causal Analysis Using 147 Summary Effect estimates) to each pair of phenotypes, with the rationale that robust 148 relationships would exhibit consistent and statistically significant results across 149 different methods. Additionally, CAUSE is the only method capable of distinguishing 150 causality from both correlated and uncorrelated pleiotropy. The relationship with at 151least 2 significant results was treated as a robust causality (Table 3). We found 152 consistent evidence for a causal effect of oral and pharynx cancer on non-Hodgkin 153 lymphoma ($P_{radial-IVW} = 6.00 \times 10^{-3}$, $P_{cause} = 8.90 \times 10^{-3}$), ovary cancer on soft tissue cancer $(P_{radial-IVW} = 1.07 \times 10^{-3}, P_{cause} = 0.01)$, kidney cancer on lung and myeloma $(P_{radial-IVW} = 0.01)$ 154 6.60×10^{-3} , $P_{cause} = 0.05$; $P_{radial-IVW} = 0.02$, $P_{cause} = 0.02$). 155 156

157 **Discussion**

With the expanded life expectancy and the prolonged survival of cancers, the incidence of SPCs has been rapidly growing in the past decades(Copur & Manapuram, 2019). Genetic factors or shared environmental factors are probably the major causes. In the previous association studies, individuals with a certain type of primary

162	malignancy would have an increased risk of another malignancy(Feller et al., 2020;
163	"Italian cancer figures, report 2013: Multiple tumours," 2013; Zheng et al., 2020).
164	However, whether there are any causal effects within the associations is unclear. In the
165	present study, via the association study based on the SEER database and the MR
166	approach using the UKB genetic dataset, we were able to perform this comprehensive
167	investigation across 26 different types of cancers. 13 out of 26 types of cancers with
168	adequate GWAS data were able to be further investigated using MR analysis. We
169	found that numbers of primary malignancies were associated with an increased risk of a
170	second primary malignancy, however, only a small part of the associations would have
171	a causal relationship (Table 2).
172	Many significant findings were observed in the SEER SIR analysis. SEER is one of
173	the largest cancer registration-based datasets making itself the most proper data source
174	to answer the study objectives; however, several advantages of this database and
175	limitations of the results should be noted. First, the results from the SEER SIR analysis
176	were associations rather than causal inferences. Many factors may influence the results
177	of the associations. For example, the confounder of screening effects may exist.
178	Patients diagnosed with primary cancer might have more frequent healthcare visits
179	compared to those who did not have any cancers. Therefore, some indolent cancers
180	such as thyroid cancer and low-risk prostate cancer could have been over-diagnosed
181	due to the screening effects. Second, it is a cancer registration-based cohort rather than
182	a population cohort, the standardized incidences calculated from the SEER database

183	may not represent the situation in the general population. Third, treatment preferences
184	and follow-up strategies may vary in different locations or institutions, which would
185	also affect the occurrence/detection of the second primary cancer. For example,
186	radiation therapy may increase the risk of cancer in nearby organs ⁶ . However, treatment
187	and follow-up information are not completed in the SEER database due to the natural
188	design of the cohort ³¹ . More importantly, lifestyles, comorbidities, and environmental
189	factors were not included in the SEER database. These are important confounders of
190	the associations between the first primary cancers and the second primary cancers.
191	The MR approaches in the current study revealed some interesting findings,
192	but several non-concordant results between MR analyses and SEER SIR were also
193	observed (Table S20). It does not indicate that the causal relationship does not exist.
194	Some factors, such as the period of follow-up, may conceal and cause false negatives
195	in the association study (SEER SIR). For example, pancreatic cancer might cause an
196	increased risk of cancers in esophagus, colon and rectum, etc. based on the MR
197	analysis in our study; however, no association was observed in SEER SIR analysis.
198	The short and poor survival of pancreatic cancer could be the most critical reason for
199	the failure of finding a positive association in the population data simply did not
200	have enough time of follow-up to observe the outcomes. Therefore, the interpretation
201	of these results should be more careful at this stage.
202	The lack of GWAS findings would be a major limitation of the MR approach

203 for some diseases as in the present study. The MR approach may only represent part of

204	the biological effects in the causal pathway between the exposure and the outcome. A
205	final causal inference should always be established based on biological mechanisms.
206	From the angle of organ location, some cancers (ovary cancer and soft tissue sarcoma)
207	might share the same tumor-related or tumor-developing environment. Besides the
208	outside therapeutic settings (radio- and chemotherapy, immuno-suppressive agents)
209	and individual factors (smoking, hormone level, certain occupational settings, HIV or
210	HPV infections, and family histories), FPC might also influence the iatrogenic
211	immune by suppressing antitumor defense mechanisms via inflammation or other
212	meditating effects (Shalapour & Karin, 2019). For instance, the increased risk of renal
213	cancer, and non-Hodgkin lymphoma were observed in immunosuppressed patients in
214	Denmark and Sweden(Hortlund et al., 2017). The immune factor might be the inner
215	relation between FPC and SPC. In our assumption, the question of mechanism should
216	be answered via cross-trait GWAS meta-analyses, searching for shared genetic
217	architecture under high heritability or potential meditation factors with comprehensive
218	database and analyses, functional experiments (tissue- or cell-specific findings) and
219	final validation in a cohort of comorbidity patients.

Finally, besides the limitations mentioned, the relatively small number of cases of some diseases in UKB may lower our statistical power. As UKB is a population-based prospective cohort, the relatively short follow-up period may not allow us to observe enough events (multiple cancers) at this stage. And it is expected to be independently replicated in another dataset. Regardless, these findings progress our

225	understanding of the relationship underlying both FPCs and SPCs, and potentially
226	provide points of exploration and intervention that may reduce second primary
227	cancers.

228

229	Conc	lusion
220	Conc	lusion

Patients who were diagnosed with a certain type of primary cancer may cause
another type of primary cancer, especially pharynx cancer on non-Hodgkin lymphoma,
ovary cancer on soft tissue cancer, kidney cancer on lung and myeloma. The profound
mechanisms need to be studied in the future.

234

235 Methods

236 *Study populations*

237 SEER Program 18 Registry database was obtained which covered 27.8% of the 238 total population in the United States("Number of Persons by Race and Hispanic 239 Ethnicity for SEER Participants - SEER Registries.,"). The SEER program is the 240 largest cancer incidence dataset in the United States based on population cancer 241 registration. Based on the ICD-10 code, we identified adult patients (age ≥ 20 years) 242 diagnosed with an FPC between 2000 and 2016, including 22 types of solid-tumor 243 sites (oral cavity and pharynx, esophagus, stomach, small intestine, colon and rectum, 244 liver, gallbladder, pancreas, larynx, lung and bronchus, bones and joints, soft tissue 245 including heart, melanoma of the skin, female breast, male breast, cervix uteri, ovary,

246	prostate, bladder, kidney, renal pelvis and ureter, brain, thyroid) and 4 types of
247	hematological malignancies (Hodgkin lymphoma, non-Hodgkin lymphoma, myeloma,
248	leukemia). Patients with diagnosis by autopsy or mentioned in the death certificate only
249	were excluded.
250	The UKB project is a prospective cohort study collecting phenotypic and genotypic
251	data from ~500,000 individuals from across the United Kingdom (median follow-up
252	time was ~14 years). The participants aged between 40 and 69 at recruitment(Bycroft et
253	al., 2018). In the present study, a total of 459,156 participants with European Ancestry
254	from UKB (release V3) with GWAS genotyping array data and imputation information
255	were obtained and included in the MR analysis. Disease phenotypes in UKB were also
256	defined using the ICD-10 code. Non-Caucasian patients were not included in the
257	present study in SEER or UKB due to the small number of subjects in UKB, which
258	made it hard to make the causal inference.
259	Written informed consent was obtained from all the participants from SEER or
260	UKB according to the established standard of the studies. The current study design was
261	reviewed by the Institutional Review Board at Ruijin Hospital (Shanghai, China).
262	
263	Genotyping and Quality Control
264	GWAS genotyping array data with imputation and QC from UK Biobank

266 (after quality control, QC) were genotyped in UKB using two similar genotyping arrays,

265

release V3 was obtained (Bycroft et al., 2018). Briefly, a total of 488,377 participants

267	the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE with 807,411 markers,
268	n=49,950) and the Applied Biosystems UK BiLEVE Axiom Array by Affymetrix
269	(825,927 markers, n=438,427). These two arrays share 95% of the markers. Individuals
270	were excluded if: (a) ancestry testing using principal component analysis (PCA) to
271	evaluate the potential conflicts between self-reported ethnicity/race and the genetic
272	ethnicity/race; (b) Poor call rate at the genotyping stage (n=968, 0.2%); (c) Mismatched
273	results between self-reported gender and genetic gender (n=652, 0.13%). The genotype
274	concordance rate was reported as>99.0% (Bycroft et al., 2018). A total of 93,095,623
275	autosomal SNPs were identified in 487,442 individuals(Bycroft et al., 2018).
276	

277 Mendelian Randomization

278 The conceptual framework was illustrated in Figure 1 and the MR study was 279 reported in accordance with the STROBE-MR guideline(Skrivankova et al., 2021). 280 Two-sample MR analyses were performed to evaluate the causality between 281 exposures (a certain primary cancer, FPC) and outcomes (another primary cancer, 282 SPC). We used previously identified disease risk-associated SNPs from the GWAS 283 Catalog database(https://www.ebi.ac.uk/gwas/)(Buniello et al., 2019). SNPs selection 284 was based on the following criteria: (1) SNPs were from a single GWAS that 285 identified the largest number of risk-associated SNPs and were conducted in 286 European ancestry; (2) SNPs reached genome-wide significant level ($P < 5 \times 10^{-8}$); (3)

287 SNPs are independent of each other in terms of linkage disequilibrium (LD, $r^2 < 0.001$)

288 and distance (>10,000 kb).

289	MR analyses derive valid estimates where the following assumptions are met: (i)
290	the SNPs are correlated with FPC, (ii) the SNPs affect SPC risk only through their
291	effects on FPC and (iii) the SNPs are independent of any confounding factors for the
292	association between FPC and SPC. For assumption (i), the strength of each instrument
293	was measured using the F statistic and the proportion of the explained variance (R^2),
294	which was considered to be sufficient if the corresponding F-statistic is >10. For
295	assumption (ii) and (iii), we searched the PhenoScanner database (available at
296	http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner)(Kamat et al., 2019;
297	Staley et al., 2016) to examine whether SNPs were significantly associated with
298	established risk factors for certain cancers, including BMI, smoking, alcohol intake
299	and physical inactivity, and excluded those at $P < 1.0 \times 10^{-5}$. Statistical power
300	calculations were performed using an online tool available at
301	https://shiny.cnsgenomics.com/mRnd/(Brion et al., 2013). The statistical power was
302	to capture an OR of 1.20 or 0.80 per a standard deviation (SD) change in the cancer
303	risk.

Inverse-variance weighted MR (IVW-MR) and MR-Egger were used in the MR analyses(Burgess et al., 2019; Burgess & Thompson, 2017; Davies et al., 2018; Hemani et al., 2018). MR would be performed based on at least 4 SNPs. Briefly, these two methods are the most used MR methods to infer a causal relationship. IVW-MR is

308	based on a random effect model and is the most efficient with the greatest statistical
309	power(Hemani et al., 2018). Potential bias as horizontal pleiotropy was evaluated and
310	adjusted via MR-Egger(Burgess et al., 2019; Burgess & Thompson, 2017; Davies et al.,
311	2018; Hemani et al., 2018). The causal inference was interpreted via IVW-MR results if
312	the horizontal pleiotropic effect was not significant; otherwise, based on MR-Egger. A
313	causal relationship will only be interpreted when a significant MR result was observed
314	from MR analyses together with a significant association based on the SEER database.
315	A series of sensitivity and robust analyses including leave-one-out, Radial
316	MR(Bowden et al., 2019; Bowden et al., 2018) and CAUSE(Morrison et al., 2020)
317	methods would be performed in case of concordant significant results. MR analyses
318	were performed using the R package "TwoSampleMR", "MendelianRandomization",
319	"RadialMR" and "cause".

320

321 Statistical Analysis

The multiple primary standardized incidence ratios (MP-SIR) were defined as the observed incidence of a second malignancy among cases previously diagnosed with a certain type of cancer divided by the expected incidence based on the SEER referent population (the SEER18 2000-2016 referent rate file). All the standardized incidence observed/expected (O/E) ratios (SIR) and the corresponding 95% confidence intervals (95% CI) were derived using the "MP-SIR" session of SEER*Stat (version 8.3.8)("Multiple Primary - Standardized Incidence Ratios - SEER*Stat.,"). Only the

329	non-Hispanic white population was included in the present study. We restricted a
330	minimum 2-month latency period between the first and second primary
331	diagnosis(Davis et al., 2014). Subgroup analyses were performed after stratifying by
332	radiation therapy (received or not). All statistical analyses were performed using
333	SEER*STAT and R software (4.1.2)(Team, 2021). A type I error of 0.05 (two-sided)
334	was used to define statistical significance. Multiplicity effects were only considered
335	during the selection of SNPs.

336

337 **Reference**

338	Bowden, J., Del Greco M, F., Minelli, C., Zhao, Q., Lawlor, D. A., Sheehan, N. A.,
339	Thompson, J., & Davey Smith, G. (2019). Improving the accuracy of
340	two-sample summary-data Mendelian randomization: moving beyond the
341	NOME assumption. International Journal of Epidemiology, 48(3), 728-742.
342	https://doi.org/10.1093/ije/dyy258
343	
344	Bowden, J., Spiller, W., Del Greco M, F., Sheehan, N., Thompson, J., Minelli, C., &
345	Davey Smith, G. (2018). Improving the visualization, interpretation and
346	analysis of two-sample summary data Mendelian randomization via the Radial
347	plot and Radial regression. International Journal of Epidemiology, 47(4),
348	1264-1278. https://doi.org/10.1093/ije/dyy101
349	
350	Brion, MJ. A., Shakhbazov, K., & Visscher, P. M. (2013). Calculating statistical
351	power in Mendelian randomization studies. International Journal of
352	Epidemiology, 42(5), 1497-1501. https://doi.org/10.1093/ije/dyt179
353	
354	Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone,
355	C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., Suveges, D.,
356	Vrousgou, O., Whetzel, P. L., Amode, R., Guillen, J. A., Riat, H. S.,
357	Trevanion, S. J., Hall, P., Junkins, H., Flicek, P., Burdett, T., Hindorff, L. A.,
358	Cunningham, F., & Parkinson, H. (2019). The NHGRI-EBI GWAS Catalog of
359	published genome-wide association studies, targeted arrays and summary
360	statistics 2019. Nucleic Acids Research, 47(D1), D1005-D1012.
361	https://doi.org/10.1093/nar/gky1120
362	
363	Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M.
364	M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., & Theodoratou,
365	E. (2019). Guidelines for performing Mendelian randomization investigations.
366	Wellcome Open Research, 4, 186.
367	https://doi.org/10.12688/wellcomeopenres.15555.2
368	
369	Burgess, S., & Thompson, S. G. (2017). Interpreting findings from Mendelian
370	randomization using the MR-Egger method. European Journal of
371	Epidemiology, 32(5), 377-389. https://doi.org/10.1007/s10654-017-0255-x
372	
373	
374	Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A.,
375	Vukcevic, D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A.,
376	Effingham, M., McVean, G., Leslie, S., Allen, N., Donnelly, P., & Marchini, J.

377	(2018). The UK Biobank resource with deep phenotyping and genomic data.
378	Nature, 562(7726), 203-209. https://doi.org/10.1038/s41586-018-0579-z
379	
380	Chattopadhyay, S., Sud, A., Zheng, G., Yu, H., Sundquist, K., Sundquist, J., Försti, A.,
381	Houlston, R., Hemminki, A., & Hemminki, K. (2018). Second primary
382	cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for
383	immune dysfunction. International Journal of Cancer, 143(10), 2449-2457.
384	https://doi.org/10.1002/ijc.31801
385	
386	Copur, M. S., & Manapuram, S. (2019). Multiple Primary Tumors Over a Lifetime.
387	Oncology (Williston Park, N.Y.), 33(7).
388	https://pubmed.ncbi.nlm.nih.gov/31365752
389	
390	Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018). Reading Mendelian
391	randomisation studies: a guide, glossary, and checklist for clinicians. BMJ
392	(Clinical Research ed.), 362, k601. https://doi.org/10.1136/bmj.k601
393	
394	Davis, E. J., Beebe-Dimmer, J. L., Yee, C. L., & Cooney, K. A. (2014). Risk of
395	second primary tumors in men diagnosed with prostate cancer: a
396	population-based cohort study. Cancer, 120(17), 2735-2741.
397	https://doi.org/10.1002/cncr.28769
398	
399	Feller, A., Matthes, K. L., Bordoni, A., Bouchardy, C., Bulliard, JL., Herrmann, C.,
400	Konzelmann, I., Maspoli, M., Mousavi, M., Rohrmann, S., Staehelin, K., &
401	Arndt, V. (2020). The relative risk of second primary cancers in Switzerland: a
402	population-based retrospective cohort study. BMC Cancer, 20(1), 51.
403	https://doi.org/10.1186/s12885-019-6452-0
404	
405	Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin,
406	C., Burgess, S., Bowden, J., Langdon, R., Tan, V. Y., Yarmolinsky, J., Shihab,
407	H. A., Timpson, N. J., Evans, D. M., Relton, C., Martin, R. M., Davey Smith,
408	G., Gaunt, T. R., & Haycock, P. C. (2018). The MR-Base platform supports
409	systematic causal inference across the human phenome. <i>ELife</i> , 7.
410	https://doi.org/10.7554/eLife.34408
411	
412	Hortlund, M., Arroyo Mühr, L. S., Storm, H., Engholm, G., Dillner, J., & Bzhalava, D.
413	(2017). Cancer risks after solid organ transplantation and after long-term
414	dialysis. International Journal of Cancer, 140(5), 1091-1101.
415	https://doi.org/10.1002/ijc.30531
416	
417	Italian cancer figures, report 2013: Multiple tumours. (2013). <i>Epidemiologia E</i>
418	Prevenzione, 37(4-5 Suppl 1). <u>https://pubmed.ncbi.nlm.nih.gov/24259384</u>

419	
420	Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J.,
421	Butterworth, A. S., & Staley, J. R. (2019). PhenoScanner V2: an expanded
422	tool for searching human genotype-phenotype associations. Bioinformatics
423	(Oxford, England), 35(22), 4851-4853.
424	https://doi.org/10.1093/bioinformatics/btz469
425	
426	Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M., & He, X. (2020).
427	Mendelian randomization accounting for correlated and uncorrelated
428	pleiotropic effects using genome-wide summary statistics. Nature Genetics,
429	52(7), 740-747. https://doi.org/10.1038/s41588-020-0631-4
430	
431	Multiple Primary - Standardized Incidence Ratios - SEER*Stat.
432	https://seer.cancer.gov/seerstat/mp-sir.html.
433	
434	Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER
435	Registries. https://seer.cancer.gov/registries/data.html#a7
436	
437	Shalapour, S., & Karin, M. (2019). Pas de Deux: Control of Anti-tumor Immunity by
438	Cancer-Associated Inflammation. Immunity, 51(1), 15-26.
439	https://doi.org/10.1016/j.immuni.2019.06.021
440	
441	Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022.
442	CA: a Cancer Journal For Clinicians, 72(1).
443	https://doi.org/10.3322/caac.21708
444	
445	Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N.
446	M., Swanson, S. A., VanderWeele, T. J., Higgins, J. P. T., Timpson, N. J.,
447	Dimou, N., Langenberg, C., Golub, R. M., Loder, E. W., Gallo, V.,
448	Tybjaerg-Hansen, A., Davey Smith, G., Egger, M., & Richards, J. B. (2021).
449	Strengthening the Reporting of Observational Studies in Epidemiology Using
450	Mendelian Randomization: The STROBE-MR Statement. JAMA, 326(16),
451	1614-1621. https://doi.org/10.1001/jama.2021.18236
452	
453	Staley, J. R., Blackshaw, J., Kamat, M. A., Ellis, S., Surendran, P., Sun, B. B., Paul, D.
454	S., Freitag, D., Burgess, S., Danesh, J., Young, R., & Butterworth, A. S.
455	(2016). PhenoScanner: a database of human genotype-phenotype associations.
456	Bioinformatics (Oxford, England), 32(20), 3207-3209.
457	https://pubmed.ncbi.nlm.nih.gov/27318201
458	
459	Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., &
460	Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of

461	Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a
462	Cancer Journal For Clinicians, 71(3), 209-249.
463	https://doi.org/10.3322/caac.21660
464	
465	Team, R. C. (2021). R: A language and environment for statistical computing.
466	https://www.R-project.org/.
467	
468	Zheng, G., Sundquist, K., Sundquist, J., Försti, A., Hemminki, A., & Hemminki, K.
469	(2020). Rate differences between first and second primary cancers may outline
470	immune dysfunction as a key risk factor. Cancer Medicine, 9(21), 8258-8265.
471	https://doi.org/10.1002/cam4.3454
472	
473	Data Availability
474	Data used in this research are publicly available to qualified researchers on
475	application to GWAS catalog (https://www.ebi.ac.uk/gwas/), the SEER database
476	(https://seer.cancer.gov/) and UK Biobank (www.ukbiobank.ac.uk).
477	
478	Author Contributions
479	R Na conceived and designed the study. XH Ruan, Da Huang processed and analyzed
480	the microarray data, performed different components of analysis and data
481	interpretations. YL Zhan provided technical support. JY Huang and JL Huang
482	provided material support. ATL Ng and JHL Tsu provided administrative support.
483	XH Ruan, D Huang and R Na wrote the manuscript. R Na made critical revision of
484	the manuscript for important intellectual content. All authors read and approved the
485	final manuscript.
486	

487 **Competing interest**

488 The authors declare that there are no competing interests.

489

490 Acknowledgement

- 491 The current study contains a part of the capstone thesis by Rong Na for Master of
- 492 Public Health at Johns Hopkins University School of Public Health (the results were
- 493 updated based on the updated datasets); otherwise, the study content has never been
- 494 published elsewhere. We would like to thank for the supervision from Professor
- 495 Jianfeng Xu from NorthShore University Health System, IL USA, Professor William
- 496 B. Issacs and Professor Bruce J. Trock from Johns Hopkins University, during Rong
- 497 Na's capstone projects. We thank SEER program to approve our protocol and provide
- 498 the custom datasets. We also thank the UK Biobank for access to the data (Project
- 499 Number: 66813).

500

501 **Funding information**

- 502 This work was in supported by grants from National Natural Science Foundation of
- 503 China (Grant No. 81972645), Innovative research team of high-level local universities
- 504 in Shanghai, Shanghai Youth Talent Support Program, intramural grant of The
- 505 University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program
- 506 (22YF1440500) to Dr. Da Huang. All the funders had no role in study design, data
- 507 collection, data analysis, interpretation, and writing of the report.
- 508

509 Figure legend

510 Figure 1. Study design and work flowchart.



511

- 512 Abbreviation: SIR, standardized incidence ratio; GWAS, genome-wide significant
- 513 association.

514

515 Figure 2. Heat-map of SIR for First primary cancers (FPC, horizontal, cancer

516 listed in the bottom) and second primary cancers (SPC, vertical, cancer listed on



517 the right) in the SEER 18 registry (2000-2016).

518

519 The SIR scale is shown in the right corner. Only significant associations (95%

520 confidence intervals not overlapping with 1.00) were included; SIRs of the

- 521 insignificant or concordant associations were assigned as 1. Abbreviations: SIR,
- 522 standardized incidence ratios; FPC, first primary cancers; SPC, second primary

523 cancers.

Cancer type	GWAS Source	PMID	Number of SNPs ^a	Cases	Total population	Variance explained, R ² , %	F-statistics
Oral and pharynx	GCST003857	27749845	7	6,034	12,619	2.22	283.68
Larynx	GCST010285	32276964	1^{b}	394	4,887	0.28	13.72
Esophagus	GCST003740	27527254	5	10,279	27,438	0.72	198.94
Stomach	GCST002990	26098866	1^{b}	2,043	202,533	0.02	34.44
Colon and rectum	GCST003017	26151821	8	18,299	37,955	0.89	340.75
Pancreas	GCST005434	29422604	14	9,040	21,536	4.28	962.28
Melanoma	GCST004142	28212542	17	6,628	293,193	0.29	852.68
Lung	GCST004748	28604730	7	29,266	85,716	0.55	474.00
Male Breast	GCST011526	32785646	2 ^b	2,190	6,836	1.27	87.91
Female Breast	GCST004988	29059683	104	122,977	228,951	4.95	11917.81
Cervix uteri	GCST004833	28806749	1^{b}	2,866	9,347	0.45	42.24
Ovary	GCST002748	25581431	9	18,530	69,745	1.16	818.42
Prostate	GCST006085	29892016	71	79,148	140,254	5.47	8111.66
Bladder	GCST002240	24163127	7	2,305	6,206	8.46	572.81
Kidney	GCST004710	28598434	8	10,784	31,190	1.11	349.99

524 Table 1. Summary of the cancer-specific instrument variables used in this study (European ancestry).

Thyroid	GCST004144	28195142	6	3,001	290,551	0.10	290.83
Myeloma	GCST004483	27363682	13	9,866	249,054	0.31	774.24

^a Number of SNPs included in the final calculation of PRS in our study; not necessarily the total number of SNPs from the source due to the

526 filtering steps discussed in the main text and germline data availability; ^b MR would be performed based on at least 4 SNPs.

527 Note: See Additional file and supplementary materials: Table S18 for the list of SNPs included in the final calculation for each phenotype.

528 No study found in European: bone and joint, brain, liver, small intestine, gallbladder, renal pelvis and ureter;

529 Heterogeneity: lymphoma, leukemia;

530 Too few SNPs: larynx, stomach, male breast cancer.

Cancer type	Can	cer type (second primary	v cancer)
(first primary cancer)	Positive Causality	Negative Causality	No Causality (statistical power≥0.80)
Oral and pharynx	Non-hodgkin lymphoma	-	Female breast, Prostate
Esophagus	-	-	-
Colon and rectum	-	-	-
Pancreas	Small intestin	-	Melanoma
Melanoma	Female breast	-	Colon and Rectum
Lung	-	Female Breast	-
Female Breast	-	-	-
Ovary	Soft tissue	-	-
Prostate	-	Colon and Rectum	Non-hodgkin lymphoma
Bladder	-	-	Female breast, Non-hodgkin lymphoma
Kidney	Lung and Bronchus, Melanoma, Non-hodgkin lymphoma, Myeloma	-	-
Thyroid	-	-	-
Myeloma	-	Lung and Bronchus	-

531 Table 2. Concordant causality between Mendelian randomization results and SEER analysis.

See Additional file: Table S20 for unconcordant causality result; Table S21-S33 for the details of Mendelian randomization results (IVW and
 MR-Egger).

Even out	Radial I	Radial IVW		lgger	CAUSE		
Exp-out	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	
Oropharynx-NH	IL 1.21 (1.13-1.30)	6.00×10 ⁻³	1.21 (1.13-1.30)	0.52	1.17 (1.05-1.31)	8.90×10 ⁻³	
Pancreas-Intest	in 1.05 (0.83-1.32)	0.69	2.39 (0.91-6.31)	0.10	1.03 (0.79-1.35)	1.00	
Melanoma-Brea	ast 1.08 (1.00-1.15)	0.06	1.05 (0.84-1.32)	0.69	1.04 (0.95-1.16)	0.75	
Lung-Breast	0.86 (0.79-0.93)	9.76×10 ⁻³	0.77 (0.54-1.08)	0.19	0.89 (0.76-1.04)	0.23	
Ovary-Soft	1.39 (1.22-1.58)	1.07×10 ⁻³	1.3 (0.74-2.29)	0.39	1.36 (1.16-1.58)	0.01	
Prostate-CRC	1.00 (0.95-1.04)	0.94	0.88 (0.80-0.98)	0.02	0.99 (0.93-1.04)	0.99	
Kidney-Lung	1.17 (1.08-1.27)	6.60×10 ⁻³	0.94 (0.62-1.43)	0.78	1.16 (1.02-1.31)	0.05	
Kidney-Melanor	ma 1.33 (1.02-1.73)	0.04	0.56 (0.18-1.80)	0.37	1.25 (0.96-1.73)	0.51	
Kidney-NHL	1.25 (1.11-1.40)	7.87×10 ⁻³	1.33 (0.72-2.46)	0.39	1.20 (0.99-1.43)	0.09	
Kidney-Myelon	na 1.72 (1.21-2.45)	0.02	0.43 (0.11-1.77)	0.29	1.49 (1.04-2.34)	0.02	
Myeloma-Lung	g 0.92 (0.86-0.98)	0.02	1.09 (0.79-1.51)	0.61	0.93 (0.86-1.00)	0.21	

534 Table 3. Sensitivity and robust analysis of the concordant causality with outlier-filtering approaches.

535 Abbreviation: IVW, Inverse variance weighted; CAUSE, Causal Analysis Using Summary Effect estimates; OR, odds ratio; CI, confidence 536 interval; exp, exposure; out, outcome; NHL, non-hodgkin lymphoma; CRC, colorectal cancer.

537